Kazuhiro Murai

16PUBLICATIONS
43CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Medical molecular engineering of nucleic acids and proteinsRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 11, 2026
Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.

|May 07, 2026
Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

|Apr 09, 2026
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Yu Sato, Takahiro Kodama, Kazuki Maesaka

|Mar 24, 2026
Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis.

Atsushi Maeda, Yuki Tahata, Hayato Hikita

|Jan 16, 2026
Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage.

Akiyoshi Shimoda, Kazuhiro Murai, Hayato Hikita

|Sep 18, 2025
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination.

Yuta Myojin, Hayato Hikita, Yuki Tahata

Pageof 3

Frequent Collaborators

13 joint publications

Takahiro Kodama

10 joint publications

Ryotaro Sakamori

8 joint publications

Tetsuo Takehara

8 joint publications

Hayato Hikita